MedTrace Logo

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

NCT05435742 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-04-12

No results posted yet for this study

Summary

The study will be conducted in adult patients with Chemotherapy-induced Peripheral Neuropathy (CIPN) that has been persistent for at least 3 months following completion of chemotherapy. A total of 60 patients will be enrolled in equal numbers of a placebo group and two different SON-080 dose groups. Treatment period will be 12 weeks long and patients will be followed-up for an additional 12 weeks.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy (CIPN)

Interventions

BIOLOGICAL

SON-080

Recombinant human interleukin-6 (rhIL-6)

Sponsors & Collaborators

  • Sonnet BioTherapeutics

    lead INDUSTRY

Principal Investigators

  • Richard Kenney, MD · Sonnet BioTherapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-27
Primary Completion
2024-03-17
Completion
2024-03-17

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435742 on ClinicalTrials.gov